Latest News about psychedelics
Recent news which mentions psychedelics
Cybin Inc's Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical Results
January 09, 2024
From Benzinga
Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
January 08, 2024
From Benzinga
Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More
January 08, 2024
From Benzinga
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
From Benzinga
Veterans Affairs, After Decades, Will Fund Psychedelic Research For Vets With PTSD And Depression
January 06, 2024
From Benzinga
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
January 06, 2024
From Benzinga
BREAKING: Ibogaine Therapy Show Promising Outcomes For Veterans With Trauma Brain Injury
January 05, 2024
Tickers
NEWS
From Benzinga
Boardroom To Rainforest, Leadership Reimagined With 1heart's Plant Medicine Approach For Global Change
January 04, 2024
Tickers
NEWS
From Benzinga
Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatment
January 04, 2024
From Benzinga
From Benzinga
AMA's Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here's What To Expect
January 03, 2024
From Benzinga
DEA Raises THC, Psilocybin And DMT Production Quotas For Scientific Research Purposes
January 02, 2024
From Benzinga
How Magic Mushrooms Affect Each Of The 5 Senses
January 01, 2024
From Benzinga
Kentucky's Promising Opioid Addiction Treatment Initiative Stalls As New AG Ousts Leading Advocate
December 29, 2023
Tickers
NEWS
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.